文献速递免疫规划传染病防控与疫情报告

加拿大B群脑膜炎奈瑟菌分离株对B群脑膜炎球菌疫苗(MenB-FHbp)的预估易感性

Estimated susceptibility of Canadian meningococcal B isolates to a meningococcal serogroup B vaccine (MenB-FHbp).
PubMed 文献 · Vaccine · 2020-01-23

研究分析了2006至2012年加拿大免疫监测计划主动监测网络收集的B群脑膜炎奈瑟菌分离株,对276株进行基因型分析,并对2010至2012年分离株测定fHbp表面表达。68.8%的276株分离株属于cc269和cc41/44两个克隆群,2010至2012年95%的MenB分离株检测到fHbp表面表达,91%的分离株fHbp表达水平预测对MenB-FHbp疫苗激发的杀菌免疫应答易感。结论为加拿大大多数MenB分离株fHbp表达水平预测足以在MenB-FHbp诱导血清抗体存在下介导补体杀菌活性。

要点

  • 68.8%的276株MenB分离株属于cc269和cc41/44两个克隆群。
  • 2010至2012年95%的MenB分离株检测到fHbp表面表达。
  • 91%的分离株fHbp表达水平预测对MenB-FHbp疫苗激发的杀菌免疫应答易感。

核心结论

  • 加拿大大多数引起脑膜炎球菌病的MenB分离株fHbp表达水平预测足以在MenB-FHbp诱导血清抗体存在下介导补体杀菌活性。

研究设计与样本

  • 研究收集2006至2012年加拿大免疫监测计划主动监测网络中的B群脑膜炎奈瑟菌分离株,对276株进行基因型分析,并对2010至2012年分离株测定fHbp表面表达。

主要发现

  • 276株分离株中68.8%属于cc269和cc41/44两个克隆群。
  • 2006至2012年分离株中共鉴定出50种不同的fHbp肽。
  • 2010至2012年95%的MenB分离株检测到fHbp表面表达。
  • 91%的分离株fHbp表达水平预测对MenB-FHbp疫苗激发的杀菌免疫应答易感。
  • 观察到一些地区差异, particularly in isolates from British Columbia and Quebec。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Invasive meningococcal disease caused by Neisseria meningitidis serogroup B (MenB) remains a health risk in Canada and globally. Two MenB vaccines are now approved for use. An understanding of the genotype of Canadian strains and the potential strain coverage conferred by the MenB-FHbp vaccine is needed to inform immunization policies. METHODS: Serogroup B Neisseria meningitidis strains responsible for meningococcal disease in Canada from 2006 to 2012 were collected as part of the Canadian Immunization Monitoring Program Active surveillance network. Genotypic analysis was done on MenB isolates from 2006 to 2012 with determination of fHbp surface expression for a subset of isolates: those occurring from 2010 to 2012. RESULTS: Two clonal complexes (cc269 and cc41/44) were observed in 68.8% of the 276 isolates. A total of 50 different fHbp peptides were identified among isolates from 2006 to 2012. Surface expression of fHbp was detected on 95% of MenB isolates from 2010 to 2012 and 91% of isolates expressed fHbp at levels that are predicted to be susceptible to the bactericidal immune response elicited by the MenB-FHbp vaccine. Some regional differences were observed, particularly in isolates from British Columbia and Quebec. CONCLUSION: The majority of MenB isolates responsible for meningococcal disease in Canada expressed fHbp at levels predicted to be sufficient for complement mediated bactericidal activity in the presence of MenB-FHbp induced serum antibodies.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Bettinger JA, Liberator P, Halperin SA, et al. Estimated susceptibility of Canadian meningococcal B isolates to a meningococcal serogroup B vaccine (MenB-FHbp). Vaccine. 2020. PMID: 31983586. doi:10.1016/j.vaccine.2019.12.051

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。